- $17.36bn
- $21.28bn
- $9.68bn
- 91
- 89
- 44
- 88
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 7.51 | ||
| PEG Ratio (f) | 0.45 | ||
| EPS Growth (f) | 20.07% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.04 | ||
| Price to Tang. Book | 31.8 | ||
| Price to Free Cashflow | 6.9 | ||
| Price to Sales | 1.79 | ||
| EV to EBITDA | 6.7 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 9.99% | ||
| Return on Equity | 10.36% | ||
| Operating Margin | 23.25% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 13,444.6 | 10,981.7 | 10,173.4 | 9,835.6 | 9,675.9 | 9,217.1 | 9,159.64 | -7.62% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -20.96 | -39.62 | +14.85 | -44.03 | +19.5 | +30.83 | +0.76 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
Directors
- Stelios Papadopoulos NEC (72)
- Michel Vounatsos CEO (59)
- Michael McDonnell CFO (57)
- Ginger Gregory CHO (53)
- Susan Alexander EVP (64)
- Alphonse Galdes EVP (68)
- Chirfi Guindo EVP (55)
- Robin Kramer SVP (55)
- Alexander Denner IND (51)
- Caroline Dorsa IND (62)
- William Hawkins IND (67)
- Nancy Leaming IND (73)
- Jesus Mantas IND (52)
- Richard Mulligan IND (66)
- Brian Posner IND (59)
- Eric Rowinsky IND (64)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 1st, 1997
- Public Since
- September 17th, 1991
- No. of Shareholders
- 392
- No. of Employees
- 7,605
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 146,374,937
- Address
- 225 Binney Street, CAMBRIDGE, 02142
- Web
- https://www.biogen.com/
- Phone
- +1 7814642000
- Auditors
- PricewaterhouseCoopers LLP
Latest News for BIIB
Upcoming Events for BIIB
Q1 2025 Biogen Inc Earnings Call
Q1 2025 Biogen Inc Earnings Release
Biogen Inc Annual Shareholders Meeting
Q2 2025 Biogen Inc Earnings Release
Similar to BIIB
Alnylam Pharmaceuticals
NASDAQ Global Select Market
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Apellis Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 19:36 UTC, shares in Biogen are trading at $118.61. This share price information is delayed by 15 minutes.
Shares in Biogen last closed at $118.61 and the price had moved by -38.28% over the past 365 days. In terms of relative price strength the Biogen share price has underperformed the S&P500 Index by -41.96% over the past year.
The overall consensus recommendation for Biogen is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreBiogen does not currently pay a dividend.
Biogen does not currently pay a dividend.
Biogen does not currently pay a dividend.
To buy shares in Biogen you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $118.61, shares in Biogen had a market capitalisation of $17.36bn.
Here are the trading details for Biogen:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: BIIB
Based on an overall assessment of its quality, value and momentum Biogen is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Biogen is $190.22. That is 60.37% above the last closing price of $118.61.
Analysts covering Biogen currently have a consensus Earnings Per Share (EPS) forecast of $15.77 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biogen. Over the past six months, its share price has underperformed the S&P500 Index by -30.88%.
As of the last closing price of $118.61, shares in Biogen were trading -30.43% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Biogen PE ratio based on its reported earnings over the past 12 months is 7.51. The shares last closed at $118.61.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Biogen's management team is headed by:
- Stelios Papadopoulos - NEC
- Michel Vounatsos - CEO
- Michael McDonnell - CFO
- Ginger Gregory - CHO
- Susan Alexander - EVP
- Alphonse Galdes - EVP
- Chirfi Guindo - EVP
- Robin Kramer - SVP
- Alexander Denner - IND
- Caroline Dorsa - IND
- William Hawkins - IND
- Nancy Leaming - IND
- Jesus Mantas - IND
- Richard Mulligan - IND
- Brian Posner - IND
- Eric Rowinsky - IND